Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Idioma
Intervalo de año de publicación
1.
Probl Endokrinol (Mosk) ; 69(6): 37-46, 2024 Jan 24.
Artículo en Ruso | MEDLINE | ID: mdl-38311993

RESUMEN

Disorders in the kidneys lead to disturbance of homeostasis. As the glomerular filtration rate decreases, the metabolism of numerous biologically active substances, including pituitary hormones, decreases. The article presents an overview of pituitary dysfunction in patients with chronic kidney disease (CKD) and discusses the possible reasons of the pathogenetic mechanisms. Particular focus is being given to the assessment of changes in the concentration of pituitary hormones in patients with end-stage chronic kidney disease (CKD) and discusses the pathogenetic mechanisms of their formation. Particular attention is paid to the assessment of changes in the concentration of pituitary hormones in patients receiving renal replacement therapy (RRT). CKD leads to an increase in the level of prolactin, luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Concentrations of growth hormone (GH), isulin-like growth factor-1 (IGF-1), thyroid-stimulating hormone (TSH), adrenocorticotropic hormone (ACTH) and vasopressin may remain within normal values or increase in this group of patients. RRT does not reduce the levels of prolactin, LH, FSH, while the concentration of growth hormone, IGF-1, TSH tends to normalize. The content of ACTH and vasopressin may remain unchanged or decrease. Kidney transplantation in most cases corrects hormonal disorders. Correction of hormonal changes can improve the clinical outcome and quality of life of patients with end stage CKD.


Asunto(s)
Hormona de Crecimiento Humana , Fallo Renal Crónico , Enfermedades de la Hipófisis , Insuficiencia Renal Crónica , Humanos , Prolactina/metabolismo , Factor I del Crecimiento Similar a la Insulina , Calidad de Vida , Hormonas Hipofisarias/metabolismo , Hormona Luteinizante/metabolismo , Hormona del Crecimiento/uso terapéutico , Hormona Folículo Estimulante/metabolismo , Tirotropina , Hormona Adrenocorticotrópica , Enfermedades de la Hipófisis/tratamiento farmacológico , Fallo Renal Crónico/terapia , Fallo Renal Crónico/tratamiento farmacológico , Vasopresinas , Insuficiencia Renal Crónica/terapia , Insuficiencia Renal Crónica/tratamiento farmacológico
2.
Probl Endokrinol (Mosk) ; 68(1): 73-80, 2021 12 06.
Artículo en Ruso | MEDLINE | ID: mdl-35262298

RESUMEN

Adipose tissue is an endocrine organ which produces a large number of secretory bioactive substances also known as adipocytokines affecting directly insulin resistance (IR), glucose and lipid metabolism, angiogenesis and inflammation. The studies show a close connection between the imbalance of adipocytokines formed as a result of excessive deposit of adipose tissue in the course of the development of type 2 diabetes mellitus and cardiovascular diseases. In the present review, we summarize current data on the effect of the adipocytokines on the liver, skeletal muscles, adipose tissue, endothelial cells and inflammatory processes, as well as attempt to define the term «adipocytokines¼ and classify adipocytokines according to their influence on metabolic processes and pro-inflammatory status. Some of adipocytokines (adiponectin, omentin, leptin, resistin, tumor necrosis factor-α and interleukin-6) are divided into two groups: adipocytokines reducing IR, and adipocytokines increasing IR.


Asunto(s)
Diabetes Mellitus Tipo 2 , Resistencia a la Insulina , Adipoquinas/metabolismo , Adiponectina , Células Endoteliales/metabolismo , Humanos , Resistencia a la Insulina/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA